Congenital dyserythropoietic anemia

Lore & Background

Congenital dyserythropoietic anemia encompasses four generally recognized types—CDA-1, CDA-2, CDA-3, and CDA-4—each with a distinct genetic cause and identifiable changes in the bone marrow. CDA-1 presents as moderate to severe macrocytic anemia, often in childhood, with enlarged spleen and liver, caused by mutations in CDAN1 or CDIN1 genes. CDA-2, the most common form, features splenomegaly, jaundice, gallstones, and iron overload, caused by SEC23B gene mutations. CDA-3 is extremely rare, found in only three families as of 2025, with giant erythroblasts in the bone marrow; it is caused by mutations in the KIF23 gene. CDA-4 is a moderate to severe anemia evident at birth, caused by a mutation in the KLF1 gene, which can be inherited in an autosomal dominant manner or arise de novo; the exact number of diagnosed cases is not firmly established.

Reader's Guide

Congenital dyserythropoietic anemia represents a critical area of study in hematology due to its rarity and the insights it provides into erythropoiesis and genetic regulation of red blood cell production. The disorders highlight the importance of bone marrow examination and genetic sequencing for accurate diagnosis, as each type has distinct microscopic features and genetic causes. Management varies from no treatment for mild cases to regular blood transfusions or stem cell transplantation for severe cases. The condition also illustrates the potential for iron overload and organ damage, necessitating careful monitoring. With fewer than a thousand cases described worldwide as of 2024, CDA remains a challenge for clinicians and researchers, but its study has advanced understanding of cell division, transcription factors, and inherited anemias. The inclusion of CDA-4, caused by a de novo mutation in KLF1, underscores the diversity of genetic mechanisms involved. The legacy of CDA lies in its contribution to the broader field of dyserythropoietic disorders and the development of targeted diagnostic and therapeutic approaches.

Did You Know?

• CDA-2 is also known as HEMPAS (hereditary erythroblastic multinuclearity with a positive acidified serum test).
• CDA-3 has only been found in three families as of 2025.

The Four Recognized Types and Their Genetic Foundations

CDA encompasses four principal subtypes, each anchored to a specific genetic defect. CDA-1 arises from mutations in either the CDAN1 or CDIN1 gene, follows an autosomal recessive pattern, and manifests as moderate to severe macrocytic anemia accompanied by abnormal chromatin visible in the bone marrow. CDA-2, the most prevalent form, is tied to the SEC23B gene with the same autosomal recessive inheritance and is distinguished microscopically by erythroblasts bearing two nuclei; it is also known by the acronym HEMPAS. CDA-3 is extraordinarily scarce, identified in only three families as of 2025, and may stem from either the KIF23 gene (autosomal dominant) or the RACGAP1 gene (autosomal recessive), both of which play essential roles in the cytokinesis phase of cell division. CDA-4 stands apart as the only subtype caused by a de novo KLF1 mutation rather than an inherited one, presenting at birth and sometimes detectable prenatally. Additional variants, including Majeed syndrome and certain sideroblastic anemias, extend the broader CDA family.

Clinical Presentation and the Diagnostic Journey

Across all CDA subtypes, patients commonly experience fatigue, generalized weakness, jaundice, and in some instances enlargement of the liver or spleen. A particularly insidious long-term complication is the body's tendency to absorb excess iron, which can progressively damage other tissues and organs. Because these manifestations overlap with numerous other hematologic and hepatic conditions, a definitive diagnosis demands a two-step clinical pathway. First, a bone marrow aspirate must be examined under the microscope to reveal type-specific morphological hallmarks—multinucleated erythroblasts in CDA-2, giant erythroblasts in CDA-3, or abnormal chromatin patterns in CDA-1. Second, genetic sequencing is performed to confirm the precise mutation and lock in the subtype classification. This combined morphological and molecular approach is indispensable, since each recognized type carries a different genetic signature and may follow distinct inheritance patterns, ranging from autosomal recessive and autosomal dominant to entirely de novo mutations.

Treatment Options and the Challenge of Extreme Rarity

Management of CDA is calibrated to severity. Mild presentations may require no medical intervention whatsoever, while more severe cases depend on regular blood transfusions to maintain adequate red blood cell levels. For the most profoundly affected patients, stem cell transplantation from a well-matched donor offers a potential curative pathway. However, the extraordinary rarity of the condition poses a persistent challenge to both research and day-to-day clinical care. As of 2024, fewer than a thousand cases have been documented worldwide, and in Europe the prevalence sits below one case per million people. CDA-3 has been identified in only three families, and CDA-4 in just ten individuals globally. This scarcity limits the pool of clinicians with hands-on experience, complicates the search for matched donors for transplantation, and slows the accumulation of long-term outcome data that would allow treatment protocols to be refined for each individual subtype.

Historical Discovery and Taxonomic Evolution

The naming and classification of CDA reflect a gradual accumulation of clinical observation spanning decades. The first cases of what would eventually be designated CDA-3 were described in 1951 under the label "familial erythroid multinuclearity," long before any broader grouping existed. It was not until 1968 that the umbrella term "congenital dyserythropoietic anemia" was formally coined, initially encompassing three recognized types. CDA-4 was added later, distinguished by its de novo KLF1 mutation rather than an inherited pattern, and some authorities place it within a wider subgroup of transcription-factor-related CD anemias. Beyond the four classic types, additional variants such as Majeed syndrome and certain forms of sideroblastic anemia have been described, further expanding the family. This evolving taxonomy underscores how the condition was pieced together incrementally, with each new genetic discovery sharpening the boundaries of what constitutes a distinct CDA subtype.